BMI View: Competition in the Japanese biosimilar market is set to intensify over the coming years.
Fundamentals attracting drugmakers into this field include its relatively nascent state, with few biosimilars
launched thus far, cost containment pressures and well-de ..."
BMI View: There will be opportunities for haemophilia products within the Japan pharmaceutical market.
The country has the third largest population of haemophilia patients in Asia, high levels of adherence and an
extensive health insurance coverage that significantly ..."
BMI View: Japanese pharmaceutical firms will be forced to adapt their business model to accommodate the
changing domestic medicine landscape. With the market share of generic drugs expected to grow in line
with government incentives, Japan-based drugmakers will see re ..."
BMI View: Japan's developed pharmaceutical market will see heightened levels of competition ahead. As a
highly saturated market with all major multinational pharmaceutical firms present, the degree of rivalry
will be further catalysed by the increasing generic drug pe ..."
BMI View: The Japanese pharmaceutical market will become increasingly challenging for multinational
drugmakers. This comes as the use of generic drugs has begun to gain momentum, creating a more
competitive environment for innovative medicines. In addition, top line g ..."
GlobalData, the industry analysis specialist, has released its latest report, "CountryFocus: Healthcare, Regulatory and Reimbursement Landscape Japan". The report is an essential source of information on and analysis of the healthcare, regulatory and reimbursement landscape in Ja ..."
BMI View: Japan's healthcare system will come under increasing financial strain due to the ageing
population and the high use of patented medicines. This provides an impetus for the government to use cost
containment measures including policies to encourage the uptake ..."
BMI View: The Japanese pharmaceutical market continues to hold strong rewards for innovative
pharmaceutical companies. This is driven by the country's rapidly ageing population, preference for branded
medicines and strong public coverage of drug expenditure. However, ..."
BMI View: The weak Japanese yen, coupled with biennial medicine price cuts, will negatively impact
multinational pharmaceutical firms operating in Japan. With effect from April 1 2014, consumption tax in
Japan was raised from 5% to 8% and the biennial pharmaceutical p ..."
BMI View: The Japanese government's push to increase generic drug use will benefit generic drug
manufacturers, particularly local firms. However, despite this support, the rate of generic drug uptake will
remain relatively low. As a result our forecasts for Japan's ge ..."